75 related articles for article (PubMed ID: 9198273)
1. Artificial-capillary-system development of human alloreactive cytotoxic T-lymphocytes that lyse brain tumours.
Kruse CA; Beck LT
Biotechnol Appl Biochem; 1997 Jun; 25(3):197-205. PubMed ID: 9198273
[TBL] [Abstract][Full Text] [Related]
2. Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2.
Kruse CA; Cepeda L; Owens B; Johnson SD; Stears J; Lillehei KO
Cancer Immunol Immunother; 1997 Oct; 45(2):77-87. PubMed ID: 9390198
[TBL] [Abstract][Full Text] [Related]
3. Restoration of cytotoxic T lymphocyte function in malignant pleural effusion: interleukin-15 vs. interleukin-2.
Chen YM; Ting CC; Peng JW; Yang WK; Yang KY; Tsai CM; Perng RP
J Interferon Cytokine Res; 2000 Jan; 20(1):31-9. PubMed ID: 10670650
[TBL] [Abstract][Full Text] [Related]
4. Preclinical studies for adoptive immunotherapy in bone marrow transplantation. Generation of anti-CD3 activated cytotoxic T cells from normal donors and autologous bone marrow transplant candidates.
Ueda M; Joshi ID; Dan M; Uberti JP; Chou TH; Sensenbrenner LL; Lum LG
Transplantation; 1993 Aug; 56(2):351-6. PubMed ID: 8356589
[TBL] [Abstract][Full Text] [Related]
5. Generation of memory CD4+, CD8+, CD45RO+ and CD16- lymphocytes activated with IL-2, INF-gamma, and TNF-alpha with specific cytotoxicity against autologous cervical cancer cells in a mixed leukocyte-tumour cell culture.
Rangel R; Rocha L; Ramirez JL; Ibarra MJ; Solorza G; Monroy A; Ramirez MA; Herrera A; Weiss-Steider B
Eur Cytokine Netw; 1995; 6(3):195-202. PubMed ID: 8589277
[TBL] [Abstract][Full Text] [Related]
6. Cloning and large-scale expansion of epitope-specific equine cytotoxic T lymphocytes using an anti-equine CD3 monoclonal antibody and human recombinant IL-2.
Mealey RH; Littke MH; Leib SR; Davis WC; McGuire TC
Vet Immunol Immunopathol; 2007 Jul; 118(1-2):121-8. PubMed ID: 17498813
[TBL] [Abstract][Full Text] [Related]
7. Anti-CD3 antibodies OKT3 and hOKT3gamma1(Ala-Ala) induce proliferation of T cells but impair expansion of alloreactive T cells; aspecifc T cell proliferation induced by anti-CD3 antibodies correlates with impaired expansion of alloreactive T cells.
Popma SH; Griswold DE; Li L
Int Immunopharmacol; 2005 Jan; 5(1):155-62. PubMed ID: 15589476
[TBL] [Abstract][Full Text] [Related]
8. B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro.
Gajewski TF
J Immunol; 1996 Jan; 156(2):465-72. PubMed ID: 8543795
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
Wong JT; Pinto CE; Gifford JD; Kurnick JT; Kradin RL
J Immunol; 1989 Nov; 143(10):3404-11. PubMed ID: 2509557
[TBL] [Abstract][Full Text] [Related]
10. Generation of cytotoxic effector lymphocytes by MLTC using tumor cells genetically modified to secrete interleukin-2.
Yamaguchi Y; Ohta K; Shimizu K; Minami K; Noma K; Hihara J; Toge T
Anticancer Res; 2001; 21(1B):669-77. PubMed ID: 11299824
[TBL] [Abstract][Full Text] [Related]
11. Lymphocytes infiltrating human ovarian tumors. I. Role of Leu-19 (NKH1)-positive recombinant IL-2-activated cultures of lymphocytes infiltrating human ovarian tumors.
Heo DS; Whiteside TL; Kanbour A; Herberman RB
J Immunol; 1988 Jun; 140(11):4042-9. PubMed ID: 3286766
[TBL] [Abstract][Full Text] [Related]
12. Human alloreactive CTL interactions with gliomas and with those having upregulated HLA expression from exogenous IFN-gamma or IFN-gamma gene modification.
Read SB; Kulprathipanja NV; Gomez GG; Paul DB; Winston KR; Robbins JM; Kruse CA
J Interferon Cytokine Res; 2003 Jul; 23(7):379-93. PubMed ID: 14511464
[TBL] [Abstract][Full Text] [Related]
13. Human mesenchymal stem cells suppress induction of cytotoxic response to alloantigens.
Angoulvant D; Clerc A; Benchalal S; Galambrun C; Farre A; Bertrand Y; Eljaafari A
Biorheology; 2004; 41(3-4):469-76. PubMed ID: 15299278
[TBL] [Abstract][Full Text] [Related]
14. Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma.
Cooper LJ; Ausubel L; Gutierrez M; Stephan S; Shakeley R; Olivares S; Serrano LM; Burton L; Jensen MC; Forman SJ; DiGiusto DL
Cytotherapy; 2006; 8(2):105-17. PubMed ID: 16698684
[TBL] [Abstract][Full Text] [Related]
15. In vitro stimulation and expansion of human tumour-reactive CD8+ cytotoxic T lymphocytes by anti-CD3/CD28/CD137 magnetic beads.
Teschner D; Wenzel G; Distler E; Schnürer E; Theobald M; Neurauter AA; Schjetne K; Herr W
Scand J Immunol; 2011 Aug; 74(2):155-64. PubMed ID: 21517928
[TBL] [Abstract][Full Text] [Related]
16. Generation of alloreactive cytolytic T lymphocytes by immobilized anti-CD3 monoclonal antibodies. Analysis of requirements for human cytolytic T-lymphocyte differentiation.
De Jong R; Brouwer M; Rebel VI; Van Seventer GA; Miedema F; Van Lier RA
Immunology; 1990 Jul; 70(3):357-64. PubMed ID: 2143171
[TBL] [Abstract][Full Text] [Related]
17. An autologous T cell clone overcomes intra-melanoma heterogeneity for susceptibility to cell-mediated lysis by using multiple lytic mechanisms: in vitro and in vivo analysis.
Mazzocchi A; Rodolfo M; Parmiani G; Anichini A
Melanoma Res; 1991; 1(3):169-76. PubMed ID: 1841713
[TBL] [Abstract][Full Text] [Related]
18. Antibody blockade of Thy-1 (CD90) impairs mouse cytotoxic T lymphocyte induction by anti-CD3 monoclonal antibody.
Haeryfar SM; Conrad DM; Musgrave B; Hoskin DW
Immunol Cell Biol; 2005 Aug; 83(4):352-63. PubMed ID: 16033530
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of the antigen-specific cytotoxic T lymphocyte-inducing ability in the PMDC11 leukemic plasmacytoid dendritic cell line via lentiviral vector-mediated transduction of the caTLR4 gene.
Iwabuchi M; Narita M; Uchiyama T; Iwaya S; Oiwa E; Nishizawa Y; Hashimoto S; Bonehill A; Kasahara N; Takizawa J; Takahashi M
Mol Med Rep; 2015 Aug; 12(2):2443-50. PubMed ID: 25936433
[TBL] [Abstract][Full Text] [Related]
20. A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III/IV astrocytoma.
Wood GW; Holladay FP; Turner T; Wang YY; Chiga M
J Neurooncol; 2000 Jun; 48(2):113-20. PubMed ID: 11083074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
